Gts Securities LLC Avadel Pharmaceuticals PLC Call Options Transaction History

Gts Securities LLC

  • $45.4 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024
SELL
$12.55 - $17.22 $439,250 - $602,700
-35,000 Reduced 46.98%
39,500 $667,000
Q4 2023

Feb 14, 2024
SELL
$9.64 - $14.59 $253,532 - $383,717
-26,300 Reduced 26.09%
74,500 $1.05 Million
Q3 2023

Nov 15, 2023
BUY
$10.3 - $15.99 $1.04 Million - $1.61 Million
100,800 New
100,800 $1.04 Million

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $650M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Gts Securities LLC Portfolio

Follow Gts Securities LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gts Securities LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email